← Russell 3000 cross-section

QSI Quantum-Si Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$185m
Revenue TTM
$2m
Net income TTM
$-98m
Free cash flow
$-94m
Composite score
30.2
Sector rank
#2904

Valuation

P / E
EV / EBITDA
EV / sales
45.9
FCF yield
-50.52%
Earnings yield vs 10-yr
-57.84pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6,138.3%
EBITDA margin
-6,588.7%
ROE
-54.7%
ROIC
-161.5%
Revenue growth
-53.0%

Insider activity, last 90 days

Net open-market
$-0.07m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations for the Three and Six Months Ended June 30, 2026 as Compared to the Three and Six Months Ended June 30, 2025 The following table presents the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2026 and 2025 (dollars in thousands): Revenue, Cost of Revenue and Gross Profit Revenue is derived from sales of products and services. Revenue, Cost of revenue and Gross profit for the three and six months ended June 30, 2026 and 2025 are as follows (dollars in thousands): Total revenue for the sale of our Platinum line of instruments, related reagent kits and service maintenance contracts decreased by $0.2 million, …Quantum-Si Inc, 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →